| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFI35 |
| Uniprot No | P80217 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-286aa |
| 氨基酸序列 | SAPLDAALHALQEEQARLKMRLWDLQQLRKELGDSPKDKVPFSVPKIPLVFRGHTQQDPEVPKSLVSNLRIHCPLLAGSALITFDDPKVAEQVLQQKEHTINMEECRLRVQVQPLELPMVTTIQMSSQLSGRRVLVTGFPASLRLSEEELLDKLEIFFGKTRNGGGDVDVRELLPGSVMLGFARDGVAQRLCQIGQFTVPLGGQQVPLRVSPYVNGEIQKAEIRSQPVPRSVLVLNIPDILDGPELHDVLEIHFQKPTRGGGEVEALTVVPQGQQGLAVFTSESG |
| 预测分子量 | 37.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFI35重组蛋白的3-4条参考文献示例(部分信息为示例性概括，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*"Expression and functional characterization of recombinant human IFI35 in antiviral immune responses"*
**作者**：Li X, Chen Y, Wang J
**摘要**：本研究成功在大肠杆菌中表达并纯化重组人IFI35蛋白，证实其通过抑制病毒RNA复制发挥抗病毒作用，并增强干扰素信号通路相关分子(如STAT1)的活性。
2. **文献名称**：*"IFI35 recombinant protein attenuates NF-κB-mediated inflammatory responses in macrophages"*
**作者**：Zhang R, Liu T, Zhou M
**摘要**：通过体外实验发现，重组IFI35蛋白可抑制LPS诱导的巨噬细胞炎症反应，机制涉及阻断NF-κB信号通路的活化，提示IFI35在自身免疫性疾病中的潜在治疗价值。
3. **文献名称**：*"Structural insights into IFI35 protein by recombinant expression and crystallography"*
**作者**：Smith A, Patel K, Kim H
**摘要**：首次报道IFI35重组蛋白的晶体结构，揭示其N端和C端结构域的关键相互作用，为解析其与病毒蛋白或宿主因子的结合机制提供结构基础。
4. **文献名称**：*"Recombinant IFI35 regulates cell apoptosis via modulating mitochondrial dynamics"*
**作者**：Wang L, Deng Y, Xu S
**摘要**：研究表明，外源性重组IFI35通过调控线粒体分裂蛋白Drp1的活性，抑制病毒感染导致的细胞凋亡，突显其在细胞存活中的双重作用。
---
**注**：以上为模拟参考文献，实际研究中请通过PubMed、Web of Science等平台检索真实文献(关键词：IFI35. recombinant protein, interferon-induced protein 35)。
**Background of IFI35 Recomcombinant Protein**
IFI35 (Interferon-induced protein 35), also known as IFI35 or NMI (N-myc interactor), is a protein encoded by the *IFI35* gene in humans. It belongs to the family of interferon-stimulated genes (ISGs), which are upregulated in response to interferon signaling during viral infections and immune challenges. Initially identified as a binding partner of N-myc oncoprotein, IFI35 has since been implicated in diverse cellular processes, including immune regulation, apoptosis, and antiviral defense. Its expression is strongly induced by type I and type II interferons, positioning it as a critical mediator in innate immunity and inflammatory responses.
Structurally, IFI35 contains a coiled-coil domain and a leucine zipper motif, facilitating protein-protein interactions. It forms homodimers or heterodimers with other proteins, such as IFI16. to modulate transcriptional activity or signal transduction pathways. Studies suggest IFI35 regulates NF-κB and STAT signaling, influencing cytokine production and immune cell functions. However, its role appears context-dependent, with evidence of both pro-inflammatory and immunosuppressive effects depending on cellular conditions.
Recombinant IFI35 protein is engineered for research to study its biochemical properties, interactions, and therapeutic potential. Produced via expression systems like *E. coli* or mammalian cells, it retains functional domains for in vitro assays, such as binding studies, enzymatic activity tests, or immune response modulation experiments. Notably, IFI35 has been linked to autoimmune diseases (e.g., lupus) and cancer progression, where dysregulation correlates with tumor growth or metastasis. Its dual role in promoting or inhibiting viral replication in different pathogens (e.g., HIV, hepatitis viruses) also makes it a focus for antiviral drug development.
Despite progress, IFI35's precise mechanisms remain incompletely understood. Ongoing research aims to clarify its regulatory networks and explore its potential as a diagnostic marker or therapeutic target in immune disorders and oncology.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
